Ivospemin

N/A

Report date: 2023/04/06 17:35:05
NME

Base Information

Drug NameIvospemin
Drug Alias Name[(HO)2-DEHSPM]Diethyl dihydroxyhomospermine - Panbela TherapeuticsSBP-101SUN-101
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis stimulantsCell division inhibitorsCaspase-3 stimulants +[5] 
TargetsCaspase-3Ornithine decarboxylasePoly (ADP-Ribose) polymerase
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructivePancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Florida
China Registration ClassN/A

Develop Information

Active CompaniesPanbela Therapeutics Inc
Inactive CompaniesSunovion Respiratory Development Inc
Active IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAdenocarcinoma

Other Information

ATC CodeN/A
Related LinksN/A